Bullfrog AI (NASDAQ:BFRGW – Get Free Report) and Ginkgo Bioworks (NYSE:DNA – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, institutional ownership and valuation.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Bullfrog AI and Ginkgo Bioworks, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bullfrog AI | 0 | 0 | 0 | 0 | 0.00 |
| Ginkgo Bioworks | 2 | 2 | 0 | 0 | 1.50 |
Ginkgo Bioworks has a consensus target price of $7.00, suggesting a potential downside of 3.58%. Given Ginkgo Bioworks’ stronger consensus rating and higher possible upside, analysts plainly believe Ginkgo Bioworks is more favorable than Bullfrog AI.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bullfrog AI | $298,798.00 | N/A | N/A | N/A | N/A |
| Ginkgo Bioworks | $170.15 million | 2.87 | -$312.76 million | ($5.01) | -1.45 |
Bullfrog AI has higher earnings, but lower revenue than Ginkgo Bioworks.
Profitability
This table compares Bullfrog AI and Ginkgo Bioworks’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Bullfrog AI | N/A | N/A | N/A |
| Ginkgo Bioworks | -259.96% | -60.27% | -26.88% |
Institutional and Insider Ownership
78.6% of Ginkgo Bioworks shares are held by institutional investors. 12.7% of Ginkgo Bioworks shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
Ginkgo Bioworks beats Bullfrog AI on 5 of the 8 factors compared between the two stocks.
About Bullfrog AI
BullFrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. It offers bfLEAP, an AI/ML platform for the analysis of preclinical and/or clinical data. The company also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.
About Ginkgo Bioworks
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for Bullfrog AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bullfrog AI and related companies with MarketBeat.com's FREE daily email newsletter.
